{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:12:10Z","timestamp":1761887530685,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.nrleng.2021.01.005","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T05:05:11Z","timestamp":1693458311000},"page":"463-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab"],"prefix":"10.1016","volume":"38","author":[{"given":"E.M.","family":"Alba Su\u00e1rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tall\u00f3n Barranco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Puertas Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Chamorro Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Robles Marhuenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2021.01.005_bib0070","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia\u2014a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0075","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s10067-014-2562-x","article-title":"Late-onset neutropenia following Rituximab treatment for rheumatologic conditions","volume":"33","author":"Breuer","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/qjmed\/hcs015","article-title":"Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center","volume":"105","author":"Besada","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.msard.2017.12.005","article-title":"Severe neutropenia after rituximab treatment of multiple sclerosis","author":"Rissanen","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0090","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheumat"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0100","unstructured":"OPERA I ClinicalTrials.gov number, NCT01247324."},{"key":"10.1016\/j.nrleng.2021.01.005_bib0105","unstructured":"OPERA II ClinicalTrials.gov number, NCT01412333."},{"key":"10.1016\/j.nrleng.2021.01.005_bib0110","unstructured":"ORATORIO ClinicalTrials.gov number, NCT01194570."},{"key":"10.1016\/j.nrleng.2021.01.005_bib0115","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony stimulating factor","volume":"54","author":"Openshaw","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0120","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","volume":"28","author":"Zanetta","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2021.01.005_bib0130","doi-asserted-by":"crossref","first-page":"102155","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer","year":"2020","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580822001614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580822001614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:35:11Z","timestamp":1761881711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580822001614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2173580822001614"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.01.005","relation":{},"ISSN":["2173-5808"],"issn-type":[{"type":"print","value":"2173-5808"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}